Diagnose and treat constipation- or diarrhoea-predominant irritable bowel syndrome with confidence

被引：0
|
作者：
Fenton, Caroline [1 ]
Kang, Connie [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2022年 / 38卷 / 04期
关键词：
MANAGEMENT; GUIDELINE;
D O I：
10.1007/s40267-022-00906-w
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Irritable bowel syndrome (IBS) is diagnosed based on clinical criteria of regular abdominal pain and disordered defaecation. If first-line treatments such as lifestyle changes fail, patients with diarrhoea-predominant IBS may respond to rifaximin, eluxadoline or, for women, alosetron, if tolerated. For constipation-predominant IBS, options are tegaserod for younger women, and the secretagogues linaclotide, plecanatide, lubiprostone and tenapanor. As IBS is a gut-brain interaction disorder, neuromodulators such as tricyclic antidepressants may help.
引用
收藏
页码：171 / 176
页数：6
相关论文
共 50 条
  • [41] Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: Role of nitric oxide
    Paragomi, Pedram
    Rahimian, Reza
    Kazemi, Mohammad Hossein
    Gharedaghi, Mohammad Hadi
    Khalifeh-Soltani, Amin
    Azary, Saeedeh
    Javidan, Abbas Norouzi
    Moradi, Kamran
    Sakuma, Stephen
    Dehpour, Ahmad Reza
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2014, 41 (02): : 118 - 126
  • [42] Xyloglucan for the treatment of diarrhoea predominant irritable bowel syndrome
    Viazis, N.
    Lolias, N.
    Pontas, C.
    Tsoukali, E.
    Karampekos, G.
    Gkeros, F.
    Filippidis, G.
    Vraka, M.
    Chatzievangelinou, C.
    Mantzaris, G. J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [43] Tenapanor for constipation-predominant irritable bowel syndrome
    Siddiqui, S.
    Cash, B. D.
    DRUGS OF TODAY, 2020, 56 (03) : 203 - 210
  • [44] LubiprostoneIn Constipation-Predominant Irritable Bowel Syndrome
    Natalie J. Carter
    Lesley J. Scott
    Drugs, 2009, 69 : 1229 - 1237
  • [45] Lubiprostone In Constipation-Predominant Irritable Bowel Syndrome
    Carter, Natalie J.
    Scott, Lesley J.
    DRUGS, 2009, 69 (09) : 1229 - 1237
  • [46] Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome
    Blake, M. R.
    Raker, J. M.
    Whelan, K.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (07) : 693 - 703
  • [47] Tegaserod for constipation-predominant irritable bowel syndrome
    Kale-Pradhan, Pramodini B.
    Wilhelm, Sheila M.
    PHARMACOTHERAPY, 2007, 27 (02): : 267 - 277
  • [48] IDIOPATHIC BILE ACID MALABSORPTION IS AN IMPORTANT CAUSE OF SYMPTOMS FREQUENTLY MISDIAGNOSED AS DIARRHOEA-PREDOMINANT IRRITABLE BOWEL SYNDROME
    Wedlake, L.
    A'Hern, R.
    Russell, D.
    Thomas, K.
    Walters, J. R. F.
    Andreyev, J.
    GUT, 2009, 58 : A6 - A7
  • [49] Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome
    Serra, Jordi
    Caballero, Noemi
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (14) : 1969 - 1974
  • [50] Bile acid malabsorption (BAM) and ileal histology in diarrhoea-predominant irritable bowel syndrome (D-IBS)
    Srinivas, M.
    Basumani, P.
    Dawson, Barbara
    Smith, M.
    Lee, John
    Bardhan, Kama D.
    GASTROENTEROLOGY, 2007, 132 (04) : A1 - A1
12345